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Abstract 22 
Angiogenesis requires co-ordination of multiple signalling inputs to regulate the behaviour of 23 
endothelial cells (ECs) as they form vascular networks. Vascular Endothelial Growth Factor 24 
(VEGF) is essential for angiogenesis and induces downstream signalling pathways including 25 
increased cytosolic calcium levels. Here we show that Transmembrane Protein 33 (tmem33) 26 
which has no known function in multicellular organisms, is essential to mediate effects of 27 
VEGF in both zebrafish and human ECs. We find that tmem33 localises to the endoplasmic 28 
reticulum in zebrafish ECs and is required for cytosolic calcium oscillations in response to 29 
Vegfa. tmem33-mediated endothelial calcium oscillations are critical for formation of 30 
endothelial tip cell filopodia and EC migration. Global or endothelial-cell specific 31 
knockdown of tmem33 impairs multiple downstream effects of VEGF including ERK 32 
phosphorylation, Notch signalling and embryonic vascular development. These studies reveal 33 
a hitherto unsuspected role for tmem33 and calcium oscillations in the regulation of vascular 34 
development. 35 
  36 
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Introduction 37 
The formation of a complex vascular network is an essential process during embryonic 38 
development which is vital for growth of tissues and is frequently dysregulated during 39 
disease in the adult. Endothelial cells (ECs) line the inner lumen of blood vessels and their 40 
organisation into complex branching networks requires co-ordination of molecular outputs 41 
coupled to specific cellular behaviours via a process primarily orchestrated by signalling from 42 
Vascular Endothelial Growth Factor (VEGF) 1.  43 
 44 
VEGF is a morphogen which signals via different ligands to induce motile and invasive 45 
behaviour which drives blood vessel sprouting. VEGFA primarily controls angiogenesis from 46 
arteries via its cognate receptor VEGFR2/KDR, while VEGFC promotes sprouting from 47 
veins via VEGFR3/FLT4 2. Migrating ECs extend filopodia to sense VEGF signals via Kdr 48 
(VEGFR2) as they form a new sprouting vessel 3. Leading angiogenic ECs are termed tip 49 
cells, which upregulate dll4 transcription, inducing Notch signalling in neighbouring cells 50 
and this acts to limit excessive angiogenic sprouting 4. Neighbouring Notch-expressing cells 51 
join the sprout as stalk cells, which in zebrafish, tend to exhibit reduced proliferative capacity 52 
compared to tip cells 4,5. 53 
 54 
VEGFA has been shown to promote proliferation of ECs in vitro via VEGFR2-mediated 55 
activation of the RAS/RAF/ERK pathway without affecting migration 6. Others, however, 56 
have shown that inhibition of ERK phosphorylation in vivo inhibits EC migration but not 57 
proliferation during angiogenesis 7. ERK activation is induced via PLCG1 phosphorylation in 58 
vitro 8 which generates inositol 1,4,5-trisphosphate (IP3). IP3 subsequently activates inositol 59 
triphosphate receptor Ca2+ channels within the endoplasmic reticulum to increase cytosolic 60 
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Ca2+ concentrations, and activate Protein Kinase C to phosphorylate ERK 9. ERK activation 61 
is required to promote angiogenesis and has been shown to promote expression of tip cell 62 
markers including dll4 7,10 and flt4 7. VEGF and Notch therefore balance formation of tip and 63 
stalk cells within developing blood vessels and modulate the relative migration and 64 
proliferation of ECs during angiogenesis 11. Ca2+ is a universal secondary messenger, which 65 
achieves specificity using complex signalling modalities. These include encoding information 66 
to activate cellular responses within cytosolic Ca2+ oscillations 12. How EC Ca2+ oscillations 67 
integrate complex molecular outputs to precisely control discrete cellular behaviours in a 68 
developing vascular network remains unknown. 69 
 70 
ECs are generally thought to be non-excitable and as such utilise store-operated calcium entry 71 
(SOCE) as their primary means to maintain Ca2+ levels in the ER after influx 13,14. The 72 
principal trigger for SOCE activation occurs when intracellular calcium stores with the ER 73 
are depleted and these are refilled via interaction of TRPC1 and ORAI1 on the plasma 74 
membrane with ER resident STIM1 which form the calcium-release activated channel 75 
(CRAC) 15-18. SOCE relies on modulation of the actin cytoskeleton, which requires Ca2+-76 
dependent proteins for ER motility 19.  77 
 78 
We have identified Transmembrane protein 33 (TMEM33) as a component of the ER Ca2+ 79 
signalling machinery required for angiogenesis. TMEM33 is a 3-pass transmembrane domain 80 
protein conserved throughout evolution with two paralogues in the budding yeast 81 
Saccharomyces cerevisiae, Pom33 and Per33 showing enrichment in the nuclear pore, and 82 
endoplasmic reticulum (ER), respectively 20,21. In the fission yeast, Schizosaccharomyces 83 
pombe, the TMEM33 orthologue Tts1p, contributes to maintenance of the cortical ER 84 
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network 22. Human TMEM33 has been shown to localise to the nuclear envelope and ER in 85 
vitro where it has been suggested to regulate the tubular structure of the ER by suppressing 86 
the membrane-shaping activity of reticulons 23,24. However, its function within the ER in vivo 87 
in multicellular organisms remains unknown. 88 
 89 
Here we describe the first characterisation of tmem33 in a multicellular organism and show 90 
that tmem33 is required in an EC-specific manner for Vegfa-mediated Ca2+ oscillations to 91 
promote angiogenesis in zebrafish embryos. The requirement for tmem33 during the response 92 
to VEGF is conserved from zebrafish to humans. Furthermore, tmem33-mediated endothelial 93 
Ca2+ oscillations are critical for formation of endothelial filopodia and contribute to activation 94 
of ERK and induction of Notch signalling to co-ordinate vascular morphogenesis.  95 
Results 96 
tmem33 knockdown impairs vascular and pronephric development 97 
We find tmem33 is expressed ubiquitously during zebrafish segmentation (Fig. 1a-c) and by 98 
26 hours post fertilisation (hpf) is enriched in the trunk vasculature and pronephros (Fig. 1d). 99 
TMEM33 expression has been previously identified within the nuclear envelope and 100 
endoplasmic reticulum in human cells 23,24. We expressed a full length C-terminal tmem33-101 
EGFP fusion mRNA in developing zebrafish and found Tmem33-EGFP fusion protein to 102 
localise to structures indicative of nuclear envelope (Fig. 1e-g, blue arrowheads) and ER (Fig. 103 
1e-g, white arrowheads) of ECs within the caudal artery.  104 
 105 
To knock down tmem33 expression and establish its function during embryonic development, 106 
we next used two splice blocking morpholinos targeting exon 3, (Supplementary Fig. 1a, b, 107 
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Supplementary Tables 1 and 2). All experiments were conducted using co-injection of both 108 
morpholinos.  tmem33 morphants exhibited reduced segmental artery (SeA) length compared 109 
to controls (Fig. 1h, i, p white arrowheads). By 30hpf, SeAs in control morphants had reached 110 
the dorsal roof of the neural tube and begun to sprout laterally to form the dorsal longitudinal 111 
anastomotic vessel (DLAV) (Fig. 1h, i yellow arrowhead), whereas tmem33 morphants often 112 
displayed abnormal spade-shaped tip cell morphology (Fig. 1k, white arrowhead) and were 113 
observed to stall at the level of the horizontal myoseptum. Consistent with this, tmem33 114 
morphants displayed reduced SeA migration rate (Supplementary Fig. 2a-d, yellow 115 
arrowheads, e). Expression of an arterial marker Tg(0.8flt1:RFP) 25 in tmem33 morphants 116 
was indistinguishable from controls and restricted to the dorsal aorta (DA) and SeAs from 117 
day 1, suggesting the DA was correctly specified in tmem33 morphants (Fig. 1i, n). Onset of 118 
circulation and blood flow was normal in tmem33 morphants (Supplementary Fig. 3, 119 
Supplementary Movies 1-3). Despite this early delay in sprouting angiogenesis, by 48 hpf, 120 
most SeAs in tmem33 morphants had completed their dorsal migration, but many failed to 121 
migrate laterally, resulting in a primitive and discontinuous DLAV (Fig. 1l-o, q, yellow 122 
arrowheads). Additionally, tmem33 morphants displayed absent parachordal 123 
lymphangioblasts (Fig. 1l, n, red arrowheads). The thoracic duct (TD) is the first major 124 
lymphatic vessel to develop in zebrafish 26 and forms by ventral migration of parachordal 125 
lymphangioblasts. In keeping with the absence of parachordal lymphangioblasts, the TD was 126 
absent in tmem33 morphants (Fig. 1s, asterisks).   127 
 128 
tmem33 knockdown reduces EC Ca2+ oscillations and filopodia 129 
VEGF signalling is essential for SeA formation in zebrafish 7,27-31 and lymphatic development 130 
26,32-36. While TMEM33 has never been implicated in angiogenesis or VEGF signalling, the 131 
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similarity of the phenotype of embryos with loss-of-function of tmem33 or VEGF signalling 132 
led us to hypothesise that tmem33 may regulate VEGF signalling in ECs. Furthermore, since 133 
VEGF increases EC intracellular Ca2+ 37, which is dependent upon the interaction of plasma 134 
membrane proteins with ER-resident proteins via SOCE 16,38, we also postulated that tmem33 135 
may regulate VEGF-induced EC Ca2+ signalling, given its indicative expression in the ER 136 
(Fig. 1e-g). 137 
 138 
To determine the effect of tmem33 knockdown on EC calcium signalling in vivo we 139 
generated an endothelial Ca2+ reporter line Tg(fli1a:gal4FFubs3;uas-gCaMP7ash392), hereafter 140 
referred to as fli1a:gal4FFubs3;uas-GCaMP7a. Recently, a similar transgenic has been 141 
employed as an indirect readout of VEGF signalling activity in zebrafish ECs 39. To first 142 
establish whether fli1a:gal4FFubs3;uas-GCaMP7a embryos reliably reported fluctuations in 143 
endothelial Ca2+ signalling, we treated embryos with Thapsigargin to inhibit the sarcoplasmic 144 
or endoplasmic reticulum Ca-ATPase (SERCA) family of Ca2+ pumps40, and thereby raise 145 
endothelial Ca2+ levels. Indeed, Thapsigargin treatment significantly increased GCaMP7a 146 
fluorescence in tip cells (Supplementary Fig. 4a, b, d) and reduced cytosolic Ca2+ oscillations 147 
in tip cells (Supplementary Fig. 4e). Conversely, since VEGF-mediated elevations in 148 
cytosolic Ca2+ are dependent upon inositol triphosphate receptor (IP3R) function37, we treated 149 
embryos with an IP3R antagonist, 2-APB to reduce cytosolic Ca2+ (Supplementary Fig. 4a, c). 150 
fli1a:GCaMP7a embryos treated with 2-APB displayed reduced EC GCaMP7a fluorescence 151 
and reduced frequency of Ca2+ oscillations in tip cells (Supplementary Fig. 4a, c, d, e).  152 
 153 
Having established fli1a:gal4FFubs3;uas-GCaMP7a as a reporter of EC cytosolic Ca2+ levels 154 
in vivo, we examined the effect of tmem33 knockdown on EC Ca2+ oscillations. tmem33 155 
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knockdown in fli1a:gal4FFubs3;uas-GCaMP7a embryos significantly reduced the frequency 156 
of Ca2+ oscillations and GCaMP7a fluorescence intensity in EC tip cells (Fig. 2a-e; 157 
Supplementary Movies 4, 5). Furthermore, treatment of fli1a:gal4FFubs3;uas-GCaMP7a 158 
embryos with the VEGFR inhibitor, Tivozanib/AV951, reduced Ca2+ oscillations in a similar 159 
manner to tmem33 knockdown (Supplementary Fig. 5a-d, i). In contrast, DAPT-mediated 160 
inhibition of Notch signalling, which negatively regulates VEGF signalling 41, significantly 161 
increased cytosolic Ca2+ oscillations within EC tip cells (Supplementary Fig. 5e, f, i). These 162 
data indicate tmem33 knockdown reduced endothelial Ca2+ activity to a similar level as 163 
VEGF inhibition, and are consistent with studies which demonstrate EC calcium signalling 164 
mediates the response to VEGF in vivo 39.  165 
 166 
The delayed SeA sprouting, abnormal tip cell morphology and aberrant DLAV anastomosis 167 
following tmem33 knockdown (Fig. 1h-o) are similar to phenotypes observed following 168 
inhibition of filopodia formation in endothelial tip cells 42. Knockdown of tmem33 in 169 
Tg(fli1a:lifeACT-mClover) sh467, which labels filamentous actin in ECs, substantially reduced 170 
the number and length of filopodia present on EC tip cells (Fig. 2j-m) suggesting defective 171 
filopodia formation may contribute to impaired angiogenesis in tmem33 morphants. Since 172 
filopodia are known to express VEGF receptors and transduce the migratory signal upon 173 
VEGF ligand binding 3,43, we examined whether loss of filopodia could account for the 174 
reduction in EC Ca2+ oscillations observed in tmem33 morphants (Fig. 2a-e, Supplementary 175 
Movies 4, 5). Tg(fli1a:lifeACT-mClover) embryos treated with the actin depolymerising agent 176 
Latrunculin B did not form filopodia (Supplementary Fig. 6a-c, black arrowheads), instead 177 
forming rapidly depolymerising F-actin foci in keeping with previous reports 42. Treatment of 178 
fli1a:gal4FFubs3;uas-GCaMP7a embryos with Latrunculin B had no significant effect on 179 
frequency of endothelial Ca2+ oscillations in tip cells in comparison to controls 180 
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(Supplementary Fig. 6d-f, white arrowheads). This suggests loss of EC filopodia in tmem33 181 
morphants is not responsible for reduced EC Ca2+ oscillations (Supplementary Fig. 6d-f, 182 
white arrowheads).  183 
 184 
tmem33 mutant zebrafish embryos display genetic compensation 185 
Since morpholino knockdown is transient and may induce off-target effects, we next 186 
generated zebrafish tmem33 mutants using transcription activator-like effector nucleases 187 
(TALENs) 44. We identified a mutant allele, (hereafter referred to as sh443) with a 2bp 188 
deletion in exon 3 that induces a premature stop codon within exon 4 encoding the second 189 
conserved transmembrane helix (Supplementary Fig. 7a, b). tmem33sh443 mutants display 190 
substantially reduced expression of tmem33 mRNA (Supplementary Fig. 7c-e) likely via 191 
nonsense-mediated decay, indicating this mutation represents a severe loss-of-function or null 192 
allele. However, in contrast to tmem33 morphants, vascular (Supplementary Fig. 7f, g) and 193 
pronephric development was normal in tmem33sh443 mutants and homozygous tmem33 mutant 194 
adults were viable. Recent studies describe mechanisms by which the zebrafish genome can 195 
compensate for genetic mutations but not morpholino knockdown 45. Consistent with such 196 
compensation, homozygous tmem33sh443 mutants injected with tmem33 morpholinos titrated 197 
to a level which did not significantly induce p53 expression (Supplementary Fig. 7h), 198 
displayed significantly longer SeAs compared to heterozygote or wild type embryos 199 
(Supplementary Fig. 7i-l, arrowheads). In addition to the described effect on vascular and 200 
lymphatic development, tmem33 morphants exhibited increased glomerular size 201 
(Supplementary Fig. 7m-o) and homozygous tmem33sh443 mutants were protected against the 202 
effect of the tmem33 morpholino on glomerular size (Supplementary Fig. 7m-o). These data 203 
suggest tmem33sh443 mutants exhibit genetic compensation or transcriptional adaptation 46. 204 
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 205 
tmem33 crispant embryos phenocopy tmem33 morphant embryos 206 
Since tmem33 mutants appeared to display genetic compensation, and in order to confirm the 207 
morpholino induced phenotype, we next knocked down tmem33 using Clustered Regularly 208 
Interspaced Short Palindromic Repeats interference (CRISPRi). This acts via steric inhibition 209 
of transcription 47 and has been previously successful in zebrafish embryos 45. In comparison 210 
to co-injection of mRNA encoding a catalytically inactive Cas9 nuclease (dCas9) 47 and 211 
control sgRNAs lacking the dCas9 binding motif (Table S3), co-injection of sgRNAs 212 
flanking the start codon of tmem33 with dCas9 mRNA  into zebrafish embryos (hereafter 213 
referred to as crispants) reduced tmem33 expression by in situ hybridisation (Supplementary 214 
Fig. 8a, b, arrowhead, Supplementary Table 2) and qRT-PCR (Supplementary Fig. 8c). 215 
tmem33 CRISPRi significantly reduced Ca2+ oscillations in tip cells (Supplementary Fig. 8d-216 
h) and endothelial filopodia number and length (Supplementary Fig. 8i-l, arrowheads). We 217 
were able to rescue the angiogenic defects in tmem33 morphants and crispants by co-injection 218 
of full length tmem33 mRNA (Supplementary Fig. 9) confirming that these were due to 219 
reduced expression of tmem33. Interestingly, at minimal phenotypic doses, induction of p53 220 
expression was substantially reduced in tmem33 crispants in comparison to tmem33 221 
morphants injected with 4ng morpholino (Supplementary Fig. 8m), suggesting CRISPRi may 222 
be less subject to non-specific effects than morpholinos. Taken together, these data 223 
demonstrate that transcriptional inhibition of tmem33 via CRISPRi induces endothelial 224 
defects highly similar to those generated by morpholino-mediated translational inhibition of 225 
tmem33 (Fig. 2). These data indicate tmem33 is required for endothelial cytosolic Ca2+ 226 
oscillations, endothelial filopodia formation and normal angiogenesis.  227 
 228 
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tmem33 promotes angiogenesis in an EC- specific manner 229 
The morphant and crispant phenotypes described above were induced by global 230 
translational/transcriptional inhibition, and tmem33 is expressed in tissue other than ECs and 231 
the developing kidney. We therefore sought to examine the effect of EC- and pronephros-232 
specific inhibition of tmem33. Since CRISPRi employs a genetically encoded catalytically 233 
inactive Cas9 nuclease (dCas9) 47, we postulated that co-expressing dCas9 under the control 234 
of a tissue specific promoter and gene targeting sgRNAs, may facilitate tissue specific 235 
knockdown of tmem33. We therefore generated fli1a:dCas9, cryaa:cfp and enpep:dCas9, 236 
cryaa:cfp constructs (Supplementary Fig. 10a, b) that drive transient dCas9 expression under 237 
control of either EC or pronephros-specific promoters respectively. These constructs were 238 
injected alongside Tol2 mRNA and gene targeting sgRNAs to elicit tissue specific gene 239 
knockdown. 240 
 241 
In comparison to co-injection of dCas9 mRNA and control sgRNAs lacking the dCas9 242 
binding motif (Supplementary Fig. 10c, arrowheads, g arrows, k, l), co-injection of sgRNAs 243 
targeting tmem33 and dCas9 mRNA into progeny of an intercross between Tg(fli1a:AC-244 
TagRFP)sh511/+ and Tg(wt1b:egfp)/+ fish induced both abnormal vascular and pronephric 245 
development (Supplementary Fig. 10g, arrowheads h, arrows k, l,) as previously 246 
demonstrated. In contrast, embryos injected with tmem33 sgRNAs and fli1a:dCas9, cryaa:cfp 247 
construct displayed significantly reduced DLAV continuity but normal kidney development 248 
(Supplementary Fig. 10e, arrowheads i, arrows k, l,), whereas embryos injected with tmem33 249 
sgRNAs and enpep:dCas9, cryaa:cfp construct, restricting CRISPRi knockdown to the 250 
kidney, developed distended glomeruli, while the vasculature was normal (Supplementary 251 
Fig. 10f, arrowheads j, arrows k, l). We next generated a stable transgenic line expressing 252 
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dCas9 in ECs, Tg(fli1a:dCas9, cryaa-cerulean)sh512, hereafter referred to as Tg(fli1a:dCas9). 253 
To avoid the potential for reduced of knockdown efficiency by fluorescent tagging, we 254 
employed untagged dCas945. We screened for embryos expressing dCas9 in ECs by in situ 255 
hybridisation (Fig. 3a-c) and validated EC restricted expression of dCas9 using 256 
immunohistochemistry (Fig. 3d-g). Since co-injection of dCas9 mRNA and control sgRNAs 257 
were consistent with normal vascular and pronephric development (Supplementary Fig. 8, 258 
S10), to test efficacy of EC gene knockdown in stable dCas9 expressing transgenics, we first 259 
injected progeny of outcrosses from Tg(fli1a:dCas9)/+ x Tg(fli1a:EGFP)/+ with an sgRNA 260 
targeting dll4 (Fig. 3h-j). Injection of sgRNA therefore served as an internal control in CFP 261 
negative embryos. CFP positive embryos displayed significantly increased DLAV diameter 262 
in comparison to CFP negative embryos (Fig. 3h, j, arrowheads, j), consistent with previously 263 
observed ectopic DLAV sprouting in dll4 morphants and mutants 48. Injection of tmem33 264 
sgRNAs into Tg(fli1a:dCas9) embryos delayed SeA sprouting (Fig. 3k-m, compare white 265 
arrowheads with yellow arrowheads) and induced discontinuous DLAV formation (Fig. 3n-p, 266 
yellow arrowheads) only in CFP positive embryos, similarly to tmem33 morphants (Fig. 1h-267 
o) and crispants (Supplementary Fig. 10c-e, arrowheads, K). Furthermore, Tg(fli1a:dCas9) 268 
embryos injected with tmem33 sgRNA displayed absent parachordal lymphangioblasts (Fig. 269 
3n, o, red arrowheads) only in CFP positive embryos, similar to tmem33 morphants (Fig. 1l-270 
o, red arrowheads). By contrast, Tg(fli1a:dCas9) embryos injected with tmem33 sgRNA 271 
displayed no significant difference in glomerular area between CFP positive and negative 272 
embryos (Fig. 3q-s, arrows). Collectively, these data demonstrate tissue specific CRISPRi-273 
mediated uncoupling of tmem33 functions within the endothelium and pronephros and 274 
indicate EC-specific and pronephros-specific functions of tmem33 during angiogenesis and 275 
pronephric development respectively in zebrafish. Importantly, all approaches to knockdown 276 
tmem33 function were compatible with normal gross embryonic morphology at phenotypic 277 
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doses (Supplementary Fig. 11). 278 
 279 
tmem33 functions downstream of VEGF during angiogenesis 280 
Elevations in cytosolic Ca2+ are induced when EC tip cells respond to extracellular Vegfa via 281 
the Kdrl receptor 39 and EC Ca2+ oscillations are reduced in tip cells following tmem33 282 
knockdown (Fig. 2a-e, Supplementary Movies 4, 5, Supplementary Fig. 8D-H). We therefore 283 
sought to establish epistasis between VEGF signalling and tmem33. We overexpressed 284 
vegfa165 mRNA, which increases EC Ca2+ signalling (Supplementary Fig. 5g, h, j) and 285 
examined the effect on EC Ca2+ activity in the presence or absence of tmem33 CRISPRi 286 
knockdown (Fig. 4a-d, i, Supplementary Movies 6-9). As expected, vegfa165 overexpression 287 
increased the frequency of cytosolic Ca2+ oscillations in endothelial tip cells (Fig. 4 a, b, 288 
arrowheads, i) but this was significantly reduced by simultaneous tmem33 knockdown by 289 
CRISPRi (Fig. 4 d, i) similarly to knockdown of tmem33 alone without vegfa165 290 
overexpression (Fig. 4a, c, d, i). Thus, tmem33 is required for Vegfa induced Ca2+ oscillations 291 
in endothelial tip cells.  292 
 293 
In addition, Vegfa promotes proliferation of intersegmental vessel (ISV) ECs via a process 294 
normally limited by Notch signalling 4. We therefore asked whether tmem33 knockdown 295 
suppresses EC number in ISVs. Vessels are referred to as ISVs where the transgene 296 
employed did not allow distinction between SeAs and SeVs. Knockdown of tmem33 reduced 297 
EC number within ISVs, similarly to previous studies following VEGF inhibition5. 298 
Furthermore, VEGF receptor expression was unaffected in tmem33 crispants (Fig. 4i). Taken 299 
together, these data demonstrate that tmem33 mediates the effects of VEGF during 300 
angiogenesis and is required for VEGF-mediated cytosolic Ca2+ signalling within endothelial 301 
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tip cells. Furthermore, these data suggest tmem33 knockdown inhibits EC proliferation in 302 
response to VEGF. 303 
 304 
TMEM33 is required for VEGFA-mediated angiogenesis in HUVECs 305 
Since tmem33 mediates the effects of Vegfa in zebrafish, we next sought to establish whether 306 
this was conserved in humans. We used RNAi to knockdown TMEM33 in Human Umbilical 307 
Vein Endothelial Cells (HUVECs) (Fig. 5a) and examined the effect on EC migration and 308 
tube formation in response to VEGFA (Fig. 5b). Consistent with our findings in zebrafish, 309 
TMEM33-deficient HUVECs migrated less than controls (Fig. 5b). In addition, HUVEC 310 
tubular morphogenesis induced by VEGFA was significantly reduced by TMEM33 311 
knockdown (Fig. 5c), indicating the requirement for TMEM33 during the response to VEGFA 312 
is conserved in humans. 313 
 314 
tmem33 knockdown reduces EC Notch and ERK signalling  315 
VEGF signalling via VEGF receptor 2 (kdr), and VEGFR4 (kdrl) in zebrafish, induces 316 
transcription of dll4 in endothelial tip cells via the MEK-ERK signalling pathway. 317 
Upregulation of Dll4 in endothelial tip cells induces Notch signalling in neighbouring stalk 318 
cells which balance tip and stalk cell identity via regulation of VEGFR expression 7,41. Since 319 
tmem33 mediates the response to VEGF, we examined whether Dll4/Notch signalling was 320 
perturbed by tmem33 knockdown. Using a transgenic Notch reporter Tg(csl:venus) 49 which 321 
reliably reports endothelial Notch signalling (Supplementary Fig. 12a-f), we observed no 322 
significant differences in reporter expression at 26hpf, (Fig. 6a, b red arrowhead, c), but by 323 
48hpf, Notch reporter expression was significantly reduced in the DA (Fig. 6d, e, red 324 
arrowheads, f) and SeAs displayed reduced Venus fluorescence in tmem33 morphants (Fig. 325 
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6d, e, white arrowheads). In keeping with this, expression of dll4, notch1b and the Notch 326 
targets hey2/gridlock and her12 were reduced by tmem33 knockdown using global CRISPRi 327 
at 48hpf but not 26hpf (Fig. 6g, h, Supplementary Table 3). In situ hybridisation confirmed 328 
reduced arterial expression of all genes assayed by qPCR at 48hpf (Fig. 6i-p, arrowheads). 329 
Phosphorylation of the serine/threonine kinase ERK preferentially occurs in angiogenic ECs7. 330 
In keeping with this requirement downstream of VEGF signalling during angiogenesis, 331 
tmem33 knockdown reduced phosphorylated ERK (pERK) in sprouting SeAs (Fig. 6q-t white 332 
arrowheads). pERK promotes expression of dll4 in zebrafish angiogenic ECs 7,10 and dll4 333 
expression was reduced by tmem33 knockdown (Fig. 4i, 6h, j, n, arrowheads). These data 334 
indicate tmem33 is required for ERK phosphorylation and Notch signalling which act 335 
downstream of VEGF in angiogenic ECs.  336 
 337 
Since tmem33 promotes sprouting angiogenesis cell autonomously (Fig. 3), we examined 338 
whether several other molecular and cellular consequences of tmem33 inhibition were due to 339 
tmem33 function within ECs. Similar to knockdown of tmem33 by morpholino and CRISPRi, 340 
Tg(fli1a:dCas9) embryos injected with tmem33 sgRNA displayed reduced endothelial Ca2+ 341 
oscillations (Supplementary Fig. 13a-c, white arrowheads), reduced filopodia number and 342 
length (Supplementary Fig. 13d-g, black arrowheads), reduced EC number in ISVs 343 
(Supplementary Fig. 13h-j) and reduced endothelial Notch signalling (Supplementary Fig. 344 
13k-m, arrowheads) in CFP positive embryos in comparison to CFP negative siblings. 345 
Collectively, this indicates tmem33 is required cell autonomously to promote endothelial Ca2+ 346 
oscillations, filopodia formation, Notch signalling and to regulate EC number during 347 
angiogenesis. 348 
 349 
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SOCE inhibition inhibits angiogenesis  350 
Although tmem33 knockdown impairs angiogenesis and reduces endothelial cytosolic Ca2+ 351 
oscillations, it was possible that these effects were due to different roles of tmem33 rather 352 
than causally linked. We therefore sought to determine whether inhibiting EC cytosolic Ca2+ 353 
release was sufficient to cause the observed phenotype of tmem33 knockdown. We inhibited 354 
SOCE using SKF-96365, a compound which inhibits STIM1 and TRPC1 function 7,50. SKF-355 
96365 treatment between 21hpf and 27hpf reduced SeA length (Fig. 7a-c arrowheads) as 356 
induced by tmem33 knockdown (Fig. 1j, k white arrowheads). Embryos treated from 21hpf 357 
until 50hpf displayed incomplete DLAV formation (Fig, 7, d-f, arrowheads) similarly to 358 
tmem33 knockdown (Fig. 1n, o). Importantly, while tmem33 expression was unaffected by 359 
SKF-96365 treatment (Fig. 7g), frequency of endothelial Ca2+ oscillations was significantly 360 
reduced in tip cells (Fig. 7h-j). Furthermore, Notch reporter expression (Fig. 7k-m) and 361 
endothelial tip cell filopodia number (Fig. 7n-p) was reduced in ECs following SKF-96365 362 
treatment similarly to tmem33 knockdown (Fig. 6d-f and Fig. 2j-m respectively). SKF-96365 363 
treated embryos also displayed abnormal spade shaped tip cell morphology (Fig. 7b, e, o, 364 
blue arrowheads) as induced by tmem33 knockdown (Fig. 1k, white arrowhead). Given the 365 
similar angiogenic defects induced by tmem33 knockdown and SKF-96365 treatment, we 366 
examined whether inhibition of SOCE could account for reduced EC number and migration 367 
previously observed in tmem33 morphants (Fig. 4e-h, j, Supplementary Fig. 2). We treated 368 
embryos from 21hpf until 30hpf and quantified EC proliferation and migration in the 369 
presence and absence of SKF-96365 between 24 and 30hpf (Supplementary Fig. 14 and 370 
Supplementary Movies 10, 11) and observed that both SeA migration (Supplementary Fig. 14 371 
a-e, arrowheads) and tip and stalk cell proliferation (Supplementary Fig. 14a-d, f-h) were 372 
significantly reduced in migrating SeAs treated with SKF-96365. Consistent with this, 373 
expression of VEGF receptors in tmem33 crispants were unaffected (Fig. 4i) and thus 374 
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unlikely to account for reduced EC number (Fig. 4f-h, Supplementary Fig. 13h-j). 375 
Collectively, these data demonstrate that SOCE inhibition impairs angiogenesis in vivo by 376 
limiting EC migration, proliferation, disrupting signalling pathways downstream of VEGF 377 
and inhibiting filopodia formation similarly to tmem33 knockdown. This is consistent with 378 
our hypothesis that reduced cytosolic EC Ca2+ oscillations account for the angiogenic defects 379 
observed caused by tmem33 knockdown. Thus, tmem33 is essential for VEGF-mediated 380 
endothelial Ca2+ oscillations that are required for tip cell filopodia formation, the downstream 381 
consequences of VEGF signalling and developmental angiogenesis (Fig. 8). 382 
  383 
Discussion 384 
No previous study has examined the function of tmem33 in a multicellular organism. 385 
Previous studies in yeast 20-22 and transformed human cells 23,24 had localised tmem33 to the 386 
endoplasmic reticulum, but no function has been demonstrated during development. We find, 387 
tmem33 is expressed widely throughout the developing zebrafish embryo and localised to 388 
structures indicative of endoplasmic reticulum in zebrafish ECs. In keeping with its 389 
expression patterns, tmem33 knockdown demonstrated a requirement for tmem33 during 390 
normal angiogenesis and pronephric development. Furthermore, TMEM33 is also required 391 
for VEGFA-mediated angiogenesis in human ECs, indicating a conserved function between 392 
zebrafish and human. 393 
 394 
We find that tmem33 is required for Vegfa-mediated cytosolic Ca2+ oscillations in endothelial 395 
tip cells. While increases in cytosolic Ca2+ are a well-established response to VEGF in ECs 396 
37,  it remained unclear whether Ca2+ signalling was required for its effects in vivo and if so, 397 
how Ca2+ co-ordinated EC behaviours during angiogenesis. Recent studies have established 398 
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that Vegfa/Kdrl signalling is required for endothelial Ca2+ oscillations during sprouting 399 
angiogenesis in vivo 39. Our findings are consistent with these, since VEGFR inhibition 400 
abrogated Ca2+ oscillations and overexpression of vegfa165 mRNA or Notch inhibition 401 
increased Ca2+ oscillations in tip cells. Reduction of Ca2+ oscillations in tip cells following 402 
either tmem33 knockdown or acute SOCE inhibition, were associated with reduced formation 403 
of filopodia, abnormal tip cell migration and aberrant anastomosis. Impaired SeA migration 404 
and DLAV anastomosis have been observed in embryos with reduced EC filopodia 405 
formation, suggesting this may contribute to the angiogenic defects induced by tmem33 406 
knockdown 42. Importantly, the frequency of cytosolic Ca2+ oscillations in tip cells was 407 
unaffected following loss of filopodia. This is in keeping with studies which demonstrated tip 408 
cells without filopodia retained their ability to respond to Vegfa 42 and suggests reduced 409 
filopodia formation induced by tmem33 knockdown was secondary to reduced EC Ca2+ 410 
oscillations. Ca2+ oscillations have been reported to promote F-actin reorganisation and cell 411 
migration in vitro 51,52. It therefore seems likely that tmem33-mediated cytosolic Ca2+ 412 
oscillations induced by VEGF signalling promote tip cell migration in vivo via organisation 413 
of the actin cytoskeleton. As such, tmem33-mediated Ca2+ oscillations permit tip cells to 414 
respond quickly to the proangiogenic Vegfa stimulus. 415 
 416 
Vegfa-mediated activation of ERK signalling is also required for angiogenic sprouting and 417 
induction of tip cell marker expression including dll4 7,10,33,53. tmem33 knockdown reduced 418 
ERK phosphorylation and Dll4/Notch signalling and delayed tip cell migration in a similar 419 
way to ERK inhibition 7,53 without significantly affecting vegfr expression. This indicates 420 
tmem33 function contributes to activation of these pathways in vivo, likely via Ca2+-421 
dependent mechanisms downstream of Vegfa. Interestingly, induction of Dll4/Notch 422 
signalling at 26hpf was not dependent on tmem33 function, however, its attenuation at 48hpf, 423 
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suggests tmem33 contributes to maintenance of Dll4/Notch signalling in ECs. Consistent with 424 
this, inhibition of SOCE reduced Notch reporter activity at 48hpf, suggesting an input from 425 
VEGF-mediated calcium signalling between 1-2dpf to maintain Dll4/Notch signalling within 426 
developing arteries. Furthermore, recent studies indicate a requirement for Ca2+ binding 427 
during folding of Notch receptors and ligand engagement, including the Dll4-Notch1 428 
interaction 54. Reduced expression of dll4 induced by tmem33 knockdown is in keeping with 429 
observed reductions in ERK phosphorylation. ERK phosphorylation is required for 430 
development of the lymphatic system 33-35,55therefore reduced ERK phosphorylation induced 431 
by tmem33 knockdown may contribute to defective lymphatic sprouting.  432 
 433 
Surprisingly, tmem33 mutants exhibited normal angiogenesis yet displayed substantial 434 
reductions in tmem33 expression. The relative ease with which one can now generate targeted 435 
lesions within the zebrafish genome and widespread adoption of these approaches by the 436 
community, has generated substantial evidence that many loss-of-function mutants fail to 437 
recapitulate morpholino-induced phenotypes 56. While this was initially attributed to well-438 
established off target effects of morpholinos 57, recent studies have indicated a greater degree 439 
of compensation within the zebrafish genome than previously considered 45. The tmem33sh443 440 
allele is predicted to generate a premature stop codon within coding exon 4, located 53 441 
nucleotides downstream of an exon junction. This is consistent with the requirement for 442 
induction of nonsense mediated decay 58 and observed reductions in tmem33 expression. It is 443 
therefore likely this allele represents a severe loss of function or null mutation and that 444 
compensatory machinery exists within the zebrafish genome to account for normal 445 
angiogenesis in tmem33sh438 mutant embryos.  446 
 447 
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To circumvent these compensatory pathways, we have developed a strategy to transiently 448 
knockdown gene function within zebrafish endothelium and pronephros using tissue-specific 449 
CRISPRi. Using this approach we were able to uncouple tissue-specific functions of tmem33 450 
and show that tmem33 is required cell autonomously in both tissues for their normal 451 
development. tmem33 functions within ECs to promote endothelial Ca2+ oscillations and 452 
filopodia formation during angiogenesis, and also to promote Notch signalling and regulate 453 
EC number. Tissue specific CRISPRi offers a relatively straightforward method to study gene 454 
function within different tissues and represents an alternative to laborious cell transplantation 455 
procedures. Tissue specific CRISPRi can be employed transiently to uncouple tissue specific 456 
functions of genes, via co-injection of gene targeting sgRNAs, dCas9 expression constructs 457 
and Tol2 mRNA. However, we observed more severe defects using this approach than when 458 
using stable transgenic lines expressing dCas9. We suspect this may be due to variable copy 459 
number integration mediated by Tol2 and thus variable dCas9 expression, in addition to 460 
inherent toxicity of DNA microinjections. At minimal phenotypic doses, CRISPRi is less 461 
prone to induction of p53 than some morpholinos and while this will vary depending upon 462 
the sgRNA, target and morpholino employed, our experience with the genes we have studied 463 
to date suggests CRISPRi may be susceptible to fewer off target effects.    464 
 465 
The localisation of tmem33 within the ER in zebrafish ECs suggest it may have an important 466 
function in regulation of endothelial SOCE. Consistent with this, acute antagonism of SOCE 467 
induced similar reductions in cytosolic Ca2+ oscillations, filopodia formation and endothelial 468 
Notch activity as tmem33 knockdown, without affecting tmem33 expression. Furthermore, 469 
SOCE inhibition reduced EC proliferation, consistent with reduced EC number induced by 470 
tmem33 knockdown. Genome-wide protein interaction studies in Drosophila embryos, have 471 
shown that the Drosophila Tmem33 orthologue, Kr-h2, physically interacts with SERCA 59, 472 
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and while this requires functional validation, the interaction appears to be conserved in 473 
humans. This suggests an ancestral function of Tmem33 in regulation of SOCE. Tmem33 474 
may also act to augment the activity of Ca2+ channels such as IP3R within the ER. 475 
Alternatively, tmem33 may be involved in mediating cortical distribution of the ER, as has 476 
been described for a yeast orthologue Tts1p22. Interestingly, rapid changes in cytosolic Ca2+ 477 
are known to induce dynamic changes in actin cytoskeleton organisation in vitro60. The actin 478 
cytoskeleton has been linked to normal SOCE function by facilitating interaction of ER 479 
resident proteins with their plasma membrane counterparts19,61. Since tmem33 knockdown 480 
reduces Ca2+ oscillations and inhibits filopodia formation, this represents an intriguing 481 
possibility. VEGF has been shown to induce distinct modalities of calcium oscillations which 482 
correlate with different EC behaviours, including migration and proliferation 62. We find that 483 
inhibition of SOCE impairs both migration and proliferation of ECs and knockdown of 484 
tmem33 similarly impairs EC migration and reduces EC number, suggesting an essential 485 
requirement for Ca2+oscillations in both processes. The endothelial actin cytoskeleton is 486 
necessary for efficient mitosis and migration and is notably disrupted by tmem33 knockdown 487 
or SOCE inhibition. This suggests that reduced EC proliferation and migration induced by 488 
inhibition of SOCE or reduced migration and EC number induced by tmem33 knockdown 489 
may represent a consequence of Ca2+-dependent disruption of the endothelial actin 490 
cytoskeleton. Further studies will be required to address the precise function of Tmem33-491 
mediated Ca2+ within the ER in ECs in response to VEGF. 492 
 493 
Methods 494 
Zebrafish strains, morpholinos and sgRNA: 495 
All zebrafish were maintained according to institutional and national ethical and animal 496 
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welfare guidelines. All experiments were performed under UK Home Office licenses 40/3708 497 
and 70/8588. The following zebrafish lines were employed: Tg(fli1a:EGFP)y1 63Tg(-498 
0.8flt1:enhRFP)hu5333 25, Tg(-26wt1b:EGFP)li1 64, Tg(flk1:EGFP-NLS)zf109 65, Tg(kdrl:HRAS-499 
mCherry-CAAX)s916 66  and Tg(csl:venus)qmc61 49. For details on mutant and transgenic line 500 
generation, see supplementary methods. 0.2 or 2ng of Sp2b and Sp3 morpholinos were 501 
injected. Where these were co-injected, a total of 0.4ng or 4ng was injected. 4ng morpholino 502 
was found to exhibit some induction of p53 (Supplementary Fig. 7h) and was titrated to 0.4ng 503 
to reduce this, however, phenotypes were equivalent at each dose. 1ng of each sgRNA was 504 
injected alongside 500pg of dCas9 mRNA45. Negative control sgRNAs contained the DNA 505 
binding element of the active gRNA but lacked the stem-loop forming region associated with 506 
binding to the Cas9 or dCas9 protein. For morpholino, sgRNA and primer sequences, see 507 
supplementary methods. 508 
Generation of tmem33sh443 mutant allele 509 
TALENs specific for tmem33 (ENSDARG00000041332) were designed against the 510 
following sequence 5’- cttcctggcccaggctt-3’ targeting an EcoNI site within exon 3. TALENs 511 
were assembled using the Golden Gate TALEN and TAL Effector Kit (Addgene, MA, USA) 512 
(Cermak et al., 2011) to generate the pTmem33Tal1L&R plasmids. Following linearisation of 513 
pTmem33Tal1L&R with NotI, capped mRNA was generated by in vitro transcription and 514 
1500pg TALEN mRNA was injected per embryo. Individual G0 embryos were tested by 515 
PCR and restriction fragment length polymorphism using tmem33ex3F and tmem33ex3R 516 
primers (Table S1) to identify somatic mutations which destroyed the EcoNI restriction site. 517 
The progeny of TALEN injected G0 adults were incrossed and genotyped to confirm 518 
presence of the sh443 allele. All studies were performed using F3 and F4 generations 519 
Generation of fli1a:dCas9 and enpep:dCas9 constructs 520 
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pME-dCas9, was generated by cloning the nls-dCas9-nls coding sequence from pT3TS-521 
dCas9, a kind gift of Didier Stainier, into pME-MCS2 which contained the multiple cloning 522 
site of pCS2+. fli1a:dCas9;cryaa:cfp and enpep:dCas9;cryaa:cfp constructs (Supplementary 523 
Fig. 10a) were subsequently generated using the Tol2 Kit via standard methods. Each 524 
construct was injected into Nacre embryos alongside Tol2 mRNA at 25pg/nl. 525 
Generation of transgenic lines  526 
Tg(fli1a:Gal4FFubs3;UAS-GCaMP7a)sh392 was generated via injection of 527 
pTol2UASGCaMP7a into progeny of tg(fli1a:Gal4FF)ubs3 67 heterozygous outcross alongside 528 
tol2 mRNA according to standard protocols 68. Tg(fli1a:LifeAct-mClover)sh467 was generated 529 
by fusing the LifeAct F-Actin binding motif 69 to the N-terminus of mClover by PCR (Table 530 
S1) to generate pME-LifeAct-mClover. fli1a:LifeAct-mClover construct was generated using 531 
the tol2 Kit via standard methods 68  and the following components; fli1a enhancer/promoter 532 
70, pME-LifeAct-mClover, pDestTol2-pA268, p3E-SV40pA68. Tg(fli1a:DsRedEx2)sh495 was 533 
generated using the tol2 Kit via standard methods 68  and the following components; fli1a 534 
enhancer/promoter 70, pENTRDSRedEx2 70, pDestTol2-pA2 68, p3E-SV40pA 68. 535 
Tg(fli1a:AC-TagRFP)sh511 was generated by amplifying the actin-VHH-TagRFP coding 536 
sequence from pAC-TagRFP (Chromotek) and adding attB1/B2R sites (Table S1) to generate 537 
pME-AC-TagRFP. fli1a:AC-tagRFP construct was generated using the Tol2 Kit 68 and 538 
components listed above. Tg(fli1a:dCas9, cryaa:Cerulean)sh512 was generated by co-539 
injecting fli1a:dCas9, cryaa:cfp plasmid with Tol2 mRNA. Embryos were injected at one-540 
cell stage with 25ng/μl Tol2 mRNA and corresponding plasmid DNA.  541 
mRNA microinjections: 542 
Microinjections of both vegfa165 63 (300pg), tmem33 (250pg) and tmem33-gfp (1200pg) 543 
mRNA were performed on single cell stage embryos with 1nl injection volume.  544 
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RNA in situ hybridisation and immunohistochemistry:  545 
Alkaline phosphatase WISH experiments were performed using standard methods as 546 
described previously 71. Detailed protocols are available upon request. EC dCas9 expression 547 
was detected using Cas9 in situ probe72. Immunohistochemistry to detect pERK was 548 
performed using Phospho-p44/42 Erk1.2 (Thr202.Tyr204) Rabbit mAb (#4370, cell signal, 549 
1:250) and quantified by normalising EC signal against ERK staining within the neural tube 550 
as described7,73. Immunohistochemistry to detect dCas9 was performed on wholemount and 551 
sectioned embryos as described74 using mouse anti-CRISPR/Cas9 (7A9-3A3) (Novus 552 
Biologicals, NBP2-36440, 1:100), chicken anti-GFP (Abcam, ab13970, 1:500) primary 553 
antibodies and goat anti-mouse IgG (H&L) Alexa Fluor® 647 (Thermo Fisher A21235, 554 
1:1000), goat anti-chicken IgY (H&L) Alexa Fluor® 488 (Thermo Fisher A11039, 1:1000) 555 
secondary antibodies. Sectioned embryos were fixed at 3dpf in 4% PFA overnight, washed 556 
into 30% sucrose and sectioned at 14μm thickness on a Jung Frigocut cryostat (Leica). 557 
Quantitative RT-PCR: 558 
qRT-PCR was performed using Taqman™ assays according to manufacturer’s instructions 559 
(see supplementary methods for probe details). RNA was extracted from batches of 20 or 30 560 
whole embryos per repeat using Trizol®, as a template for cDNA synthesis (Verso™ cDNA 561 
synthesis kit, Thermo Fisher). A 7900 Real-Time PCR system (Applied Biosystems) was 562 
used for qPCR experiments. Gene expression levels were normalised to eef1α, and for each 563 
comparison, the experimental group was normalised to their relative control unless otherwise 564 
stated.  All experiments were performed in triplicate.  Results display triplicate 2-ΔΔCT values 565 
and S.E.M (unless otherwise stated). 566 
Image acquisition and analysis 567 
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For light sheet imaging, embryos were anaesthetised using tricaine in E3 medium and 568 
mounted in 1% agarose. A light sheet Z.1 system was used and images were acquired using 569 
ZEN software (Zeiss). For confocal microscopy, still images were taken using an Ultraview 570 
VOX confocal spinning disc system (Perkin Elmer), Zeiss LSM880 with Airyscan and Leica 571 
SP5. Images were analysed using Volocity®V5.3.2, ZEN software (Zeiss) and Leica LCS 572 
Confocal software. In cases where samples displayed drift during timelapses, these were 573 
corrected using the translation algorithm in ZEN (Blue Edition).  574 
Calcium imaging 575 
Calcium oscillations were quantified using 12-14 SeAs between 24-28 hpf on a Zeiss 576 
Lightsheet Z.1. All time lapses were taken at 3µm z-intervals at 20fps with an acquisition 577 
time of 4-6 seconds per stack using a 20x objective lens for 300s. Changes in fluorescence 578 
over time were measured throughout the DA to establish a baseline. Changes in fluorescence 579 
measured in tip cells were determined to be peaks by subtracting mean DA fluorescence. 580 
Changes in fluorescence were normalised to DA baseline values. In experiments where 581 
ectopic Ca2+ oscillations were induced in the DA, the mean dorsal aorta value of control 582 
embryos was used to normalise datasets. Absolute calcium peak number was quantified and 583 
averaged per SeA, per minute. FIJI was employed to quantify fluorescence intensity. Tip cells 584 
were manually segmented as regions of interest and mean and peak fluorescence (Arbitrary 585 
units, A.U.) were determined. 586 
Pharmacological treatment: 587 
VEGF inhibition using Tivozanib/AV951 (500nM), Notch inhibition using DAPT (100μM), 588 
or inhibition of F-actin polymerisation using Latrunculin B (380nM) was conducted using 589 
dechorionated embryos between 24-28hpf in E3 medium with DMSO as a control. SERCA 590 
inhibition using Thapsigargin (5μM) was performed for 45 minutes before immediate 591 
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imaging using a PerkinElmer Spinning Disk. SOCE inhibition using SKF-963656 (50μM) 592 
dissolved in water, was performed on dechorionated embryos using untreated embryos as 593 
control. The effect of SKF-96365 treatment on EC proliferation and migration 594 
(Supplementary Fig. 14) was performed using continuous exposure to compound within a 595 
lightsheet chamber using SKF-96365 at a concentration of 50μM within 0.7% agarose 596 
mounting medium and surrounding E3 medium + Tricaine. Embryos were treated from 21hpf 597 
and imaged between 24 and 30hpf. 1-2 embryos were imaged for each individual condition 598 
and 3 congruent repeats of each condition were performed.  599 
Calculation of dorsal aorta blood flow velocimetry 600 
Single Z-plane time lapses of 3 dpf zebrafish dorsal aorta were acquired at 66 frames per 601 
second (fps) using a Zeiss Lightsheet Z.1 microscope. The resulting images were subjected to 602 
axial line scan particle image velocimetry designed for Lightsheet imaging using custom 603 
authored scripts in MATLAB 2017b ®. Each time lapse was analysed frame by frame using 604 
intensity based thresholding of circulating erythrocytes. Thresholded images were made 605 
binary followed by conversion of two dimensional (2D) image to one dimensional (1D) 606 
signal by summing up in ‘y’ direction (all column pixels).  The 1D signal was low pass 607 
filtered to remove spurious and highly correlated pixels (low correlation implies displacement 608 
of 1D wave signal). Cross correlation across time was calculated on filtered images for each 609 
time frame using inbuilt MATLAB 2017b® functions. Thus, the obtained correlation (in 610 
pixels/frames) was then converted to mm/sec using the following equation: 611 
3( / ) 10( / )
( / )
Correlation pixels frame fpsVelocity mm s
Scale pixels mμ
−× ×
=  612 
Algorithm is available on request. 613 
siRNA TMEM33 knock-down in HUVEC 614 
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siRNA-mediated knock-down of TMEM33 gene expression in human umbilical vein 615 
endothelial cells (HUVEC) was performed using ON-TARGET-plus SMART pool human 616 
TMEM33 (Thermo Scientific). ON-TARGET-plus non-targeting pool control duplexes 617 
(Thermo Scientific) were used as a control.  For siRNA transfection, HUVECs (Cellworks, 618 
ZHC-2301) were plated in 0.1% gelatin pre-coated 6-well tissue culture plates (3 x 105 619 
cells/well) and incubated overnight. The following morning, cells were washed with PBS and 620 
incubated in serum-free, antibiotic-free OPTIMEM medium for 1 hour. Then, 100 pmol of 621 
siRNA/well were transfected using 5 μl of Lipofectamine 2000 (Thermo Scientific). 622 
Transfection medium was removed after incubation for 6 hours, and substituted by ECGM 623 
supplemented with ECGM-supplement mix and 1% penicillin/streptomycin/amphotericin B 624 
(Sigma-Aldrich). Cells were incubated for 72 hours and then used for further experiments. 625 
Wound healing EC migration assay 626 
Cell migration of HUVECs and MLECs, treated as indicated, was assayed using the 627 
Cytoselect™ 24-well Wound Healing Assay kit (Cell Biolabs). Images were captured with a 628 
Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE TS100 microscope at 4× 629 
magnification. Cell-free area was quantified with ImageJ software. 630 
Matrigel EC tube-formation assay 631 
HUVECs were plated onto Geltrex Reduced Growth-Factor Matrix (Invitrogen) in Medium 632 
200 with no phenol red and supplemented with 2% foetal calf serum and 50 ng/ml growth 633 
factor (VEGF or bFGF) in the presence of ATA at the indicated concentration or DMSO as a 634 
control. Tube formation was quantified after incubation at 37 °C for 16 h. Images were 635 
recorded with a Nikon DSFi1 digital camera coupled to a Nikon ECLIPSE TS100 636 
microscope at 4× magnification. 637 
Statistical analysis 638 
All statistical analysis employed two-tailed tests and are described in figure legends. All error 639 
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bars display the mean and standard deviation except for qPCR error bars, which display the 640 
mean and standard error of the mean. Numbers of experimental repeats are listed in figure 641 
legends. P values, unless exact value is listed, are as follows: *=<0.05, **=<0.01, 642 
***=<0.001, ****=<0.0001. F-values, t-values and degrees of freedom are listed in 643 
individual figure legends. 644 
Data Availability 645 
The datasets generated during and/or analysed during the current study are available from the 646 
corresponding author on reasonable request. The source data underlying Figs 1L-M, 2B, D, 647 
E, H, I, 3G, J, M, P 4E, H, I, 5A-C, 6C, F, G, H, U, and 7C, F, G, J, M, P and Supplementary 648 
Figs 2E, 3D, 4D, E, 5B, D, F, H, I, J, 6C, F, 7E, H, L, O, 8C, E, G, H, K, L, M, 9J, K 10K, L, 649 
12C, F, 13C, F, G, J, M and 14E-H are provided as a Source Data file. A reporting summary 650 
for this Article is available as a Supplementary Information file. 651 
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Figure 1 tmem33 knockdown inhibits angiogenesis and localises to the ER in ECs. a-d) 843 
tmem33 is expressed ubiquitously during segmentation, but displays enrichment in the 844 
pronephros (black arrowheads) and somite boundaries, which is more pronounced from 24 845 
hpf. Pronephric expression is evident in 26 hpf transverse sections (black arrows). e-g) 846 
Tmem33-EGFP protein localises to the nuclear envelope (blue arrowheads) and ER (white 847 
arrowheads) within the caudal artery in fli1a:DsRedEx2 embryos (Scale bars 1µm). h-k) 848 
tmem33 morphants injected with 0.4ng morpholinos display delayed migration of 849 
Tg(fli1a:egfp) positive SeAs, which stall at the horizontal myoseptum (j, k, white 850 
arrowheads), compared to control Tg(fli1a:egfp) positive morphants (h, i), which begin to 851 
anastomose by 30 hpf (yellow arrowheads) (Scale bars 50 µm). i-o) By 48 hpf, 852 
Tg(fli1a:EGFP;-0.8flt1:RFP) tmem33 morphant SeAs complete dorsal migration, but display 853 
incomplete DLAV formation (n, o, yellow arrowheads) and lack lymphatic vasculature (red 854 
arrowheads). At 48 hpf Tg(fli1a:EGFP; -0.8flt1:RFP) control morphants display secondary 855 
angiogenesis (l, m, yellow arrowheads) and parachordal lymphangioblasts (red arrowhead) 856 
(Scale bars 50µm). p) tmem33 morphants injected with 0.4ng morpholinos display reduced 857 
SeA length at 30 hpf (t-test ****p=<0.0001 t=4.075 DF=24. n=3 repeats, 10 embryos per 858 
group). q) tmem33 morphants injected with 0.4ng morpholinos display incomplete formation 859 
of DLAV (t-test ****p=<0.0001, t=5.618 DF=28. n=3 repeats, 9 or 10 embryos per group). r, 860 
s) Thoracic duct formation is impaired in tmem33 morphants injected with 0.4ng morpholinos 861 
(white asterisks), compared to control morphants (white arrowheads) (Scale bars 50µm). 862 
Abbreviations; DA, dorsal aorta; PCV, posterior cardinal vein. Source data are provided as a 863 
Source Data file. 864 
 865 
 866 
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 867 
Figure 2 tmem33 knockdown reduces Ca2+ oscillations in tip cells and reduces EC 868 
filopodia. a-d) tmem33 morphants injected with 0.4ng morpholinos display reduced 869 
endothelial Ca2+ oscillations. Intensity projections show Ca2+ oscillations in both control and 870 
tmem33 morphants, highlighting intensity over duration of the time-lapse. Change in 871 
fluorescence over 300s for four SeAs, trace colours correspond to equivalent arrowheads 872 
(Scale bars 50 µm).  e) tmem33 morphants display a significant reduction in Ca2+ oscillations 873 
when compared to control morphants (Unpaired t-test ****p=<0.001; t=5.633; DF=10, 2 874 
repeats, n= 3 embryos per group). f, g) tmem33 morphants injected with 0.4ng morpholinos 875 
display delayed migration of SeAs which extend fewer filopodia, compared to controls (black 876 
arrowheads) (Scale bars 5 µm). h) tmem33 morphants display significantly fewer filopodia 877 
per SeA compared to controls. Measurements taken from n=4 SeAs per embryo. Unpaired t-878 
test, ****p=<0.0001; t=7.805; DF=24, 2 repeats, n= 6 or 7 embryos per group). i) tmem33 879 
morphants display reduced filopodia length compared to controls, measurements taken from 880 
n=4 SeAs. Unpaired t-test ****p<0.0001; t=10.86; DF=24; 2 repeats, n= 6 or 7 embryos per 881 
group. Source data are provided as a Source Data file. 882 
 883 
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Figure 3. Injection of sgRNAs targeting tmem33 into stable 885 
Tg(fli1a:dCas9;cryaa:CFP)sh512 embryos recapitulates knockdown of tmem33 a) dCas9 is 886 
expressed within the developing vasculature (red arrowhead) including SeAs (black 887 
arrowheads) in approximately 50% of progeny from a Tg(fli1a:dCas9;cryaa:Cerulean)sh512/+ 888 
outcross at 26 hpf. At this stage the dominant cryaa:Cerulean marker is not expressed. b) 889 
dCas9 is not expressed within the developing vasculature in CFP-  890 
Tg(fli1a:dCas9;cryaa:Cerulean)sh512 transgenic embryos at 50hpf. Probe trapping in 891 
notochord is highlighted (blue arrowhead). c) dCas9 is expressed within the dorsal aorta (red 892 
arrowhead) and SeAs (black arrowheads) in CFP+ Tg(fli1a:dCas9;cryaa:Cerulean)sh512 893 
transgenic embryos at 50hpf. Probe trapping in notochord is highlighted (blue arrowhead). d-894 
g) Colocalisation of dCas9 and GFP in 72hpf fli1a:dCas9; fli1a:EGFP embryo indicates EC 895 
restricted expression of dCas9 (white arrowheads) Scale bars 20μm. h, i) 896 
Tg(fli1a:dCas9;cryaa:Cerulean) embryos injected with sgRNA targeting dll4 phenocopies 897 
ectopic vascular looping within the DLAV previously observed in dll4 morphants and 898 
mutants at 3dpf (white arrowheads). j) Tg(fli1a:dCas9;cryaa:Cerulean) positive embryos 899 
injected with sgRNAs targeting dll4 display increased DLAV diameter (unpaired t-test 900 
***p=<0.001; t=4.203 DF=35; 2 repeats; n= 9 embryos per group). Scale bars 50 µm. k-m) 901 
Tg(fli1a:dCas9;cryaa:Cerulean) embryos injected with sgRNAs targeting tmem33 display 902 
reduced SeA length (yellow arrowheads highlight normal SeAs, white arrowheads highlight 903 
delayed SeAs) at 30hpf (unpaired t-test ***p=<0.0001; t=6.716 DF=62; 3 repeats; n=9-12 904 
embryos per group). Scale bars 50 µm. n-p) Tg(fli1a:dCas9;cryaa:Cerulean) embryos 905 
injected with sgRNAs targeting tmem33 display absent parachordal lymphangioblasts (red 906 
arrowhead) and reduced DLAV continuity (yellow arrowheads) (unpaired t-test 907 
***p=<0.0001; t=6.399 DF=56; 3 repeats; n=9-11 embryos per group). Scale bars 50 µm.  q-908 
s) Tg(fli1a:dCas9;cryaa:Cerulean) embryos injected with sgRNAs targeting tmem33 display 909 
36 
 
no significant difference in glomerular area, compared to Tg(fli1a:dCas9;cryaa:Cerulean) 910 
negative siblings  embryos (unpaired t-test ns = not significant; t=0.4048; DF=74; 3 repeats; 911 
n=12-13 embryos per group). Scale bars 200 µm. Source data are provided as a Source Data 912 
file. 913 
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Figure 4 tmem33 functions downstream of Vegfa during angiogenesis. a-e) tmem33 915 
knockdown prevents Vegfa-mediated increases in Ca2+ oscillations. Overexpression of 916 
vegfa165 significantly increases frequency of Ca2+ oscillations in SeAs, whereas tmem33 917 
knockdown alone and in the presence of vegfa165 significantly reduce frequency of Ca2+ 918 
oscillations in SeAs. Intensity projection over time showing Ca2+ oscillations highlighting 919 
intensity change over duration of time-lapse. Embryos display changes in fluorescence in 920 
SeA tip cells (white arrowheads) (2-way ANOVA with Holm-Sidak’s corrections: *p=<0.05. 921 
2 repeats, n=3 embryos per group) (Scale bars 50 µm). f-h) tmem33 knockdown using 0.4ng 922 
morpholinos reduces EC number in ISVs at 53 hpf. h) Unpaired t-test; ****p<0.0001; 923 
t=6.507; df=30; 2 repeats; n=8 embryos per group. i) VEGF receptor expression is not 924 
significantly affected in tmem33 crispants (One way ANOVA with Dunnett’s corrections; 925 
p=<0.05, n= 3 repeats). Source data are provided as a Source Data file. 926 
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Figure 5 TMEM33 is required for VEGFA-mediated angiogenesis in HUVECs. a) 928 
TMEM33 expression is significantly reduced by siRNA knockdown (b) Representative 929 
images of wound-healing migration assays performed with HUVECs transfected with a non-930 
targeting control siRNA (siRNA-NT) or a siRNA specific for human TMEM33 (siRNA-931 
TMEM33) after incubation in culture medium supplemented with VEGF (25 ng/ml). Data are 932 
shown as mean ± SE, n=9, obtained from 3 independent experiments for comparison of cells 933 
transfected with siRNA-TMEM33 vs siRNA-NT (unpaired two-tailed, Student’s t test ****, 934 
P≤0.001). Images were taken at time zero and after incubation for 24 hours. The migrated 935 
area was calculated by subtracting the value of the non-migrated area from the wound area at 936 
time zero, and expressing this as a percentage of the total area at time zero. Scale bars, 1000 937 
µm. c) HUVECs transfected as described in (A) were plated on Growth-Factor Reduced 938 
Matrix (Geltrex) in Medium 200 containing 2% FBS (Control), supplemented with VEGF 939 
(25 ng/ml) when indicated (VEGF). Images show representative fields from experiments 940 
quantified in the histogram. Data are shown as mean ± SE, n=8, obtained from 3 independent 941 
experiments. ns=non-significant; **, P≤0.01; ***, (one-way ANOVA with post hoc Tukey's 942 
comparison test P≤0.005). Scale bars, 1000 µm. Source data are provided as a Source Data 943 
file. 944 
Figure 6: tmem33 knockdown reduces endothelial Notch and ERK signalling during 945 
angiogenesis a-c) Notch reporter expression is unaffected by injection of 0.4ng tmem33 946 
morpholinos at 26 hpf. Notch signalling activity in control embryos is present in neural tube 947 
(blue arrowhead), notochord (blue asterisk) and DA (red arrowhead) (c, unpaired t-test; 948 
t=0.5553; DF=20; 2 repeats; n=5 or 6 embryos per group). Scale bars 50 µm. d-f) Injection of 949 
0.4ng tmem33 morpholinos reduces Notch reporter expression at 48 hpf. Notch expression in 950 
control Tg(csl:venus) embryos is present in the neural tube (blue arrowhead), notochord (blue 951 
asterisk), DA (red arrowhead) and SeAs (white arrowheads) (f, unpaired t-test; p=0.0451; 952 
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t=2.138; DF=20; 2 repeats; n=6 and 4 embryos per group). Scale bars 50 µm. g) Expression 953 
of notch1b, dll4, hey2 and her12 are not significantly altered by tmem33 CRISPRi at 26 hpf 954 
(One-way ANOVA using post hoc Tukey's comparison test. n=3 repeats). h) Expression of 955 
notch1b, dll4, hey2 and her12 are significantly reduced at 48 hpf by tmem33 CRISPRi (One-956 
way ANOVA using post hoc Tukey's comparison test. *p=<0.05; **p=<0.01. n=3 repeats). i-957 
p) In comparison to control morphants (i-l), embryos injected with 0.4ng tmem33 morpholino 958 
(M-P) display reduced expression of notch1b within the DA (i, m red arrowheads) and SeAs 959 
(i, m white arrowheads), dll4 within SeAs (j, n, white arrowheads), hey2 within the DA (k, o, 960 
red arrowheads) and her12 within the DA (l, p red arrowheads) and SeAs (l, p white 961 
arrowheads). Scale bars 100 µm. q-t) tmem33 knockdown by CRISPRi reduces endothelial 962 
ERK phosphorylation. (q, r, SeAs highlighted by yellow outline and white arrowheads).  963 
Intensity plot of ERK staining is shown (s, t, SeAs highlighted by yellow outline and white 964 
arrowheads). Scale bars 50 µm.  u) tmem33 crispants display significantly reduced levels of 965 
pERK phosphorylation. Pixel intensity normalised to neural tube ERK fluorescence (unpaired 966 
t-test, **p=0.0097, t=2.993 DF=14. n=2 repeats, 4 embryos per group). Source data are 967 
provided as a Source Data file. 968 
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Figure 7 SOCE inhibition limits sprouting angiogenesis and disrupts signalling 970 
pathways downstream of VEGF. a, b) SKF9635 impairs angiogenesis in Tg(fli1a:EGFP) 971 
embryos (white arrowheads) and induces abnormal tip cell morphology (blue arrowhead) by 972 
27 hpf. Scale bars 50 µm. c) SKF96365 treated embryos display reduced SeA length by 27 973 
hpf (unpaired t-test; p=<0.0001; t=11.22 DF=14; 2 repeats, n=4 embryos per group). d, e) 974 
SKF96365 treatment impairs DLAV formation (white asterisks) in comparison to control 975 
embryos, which form the DLAV normally by 50 hpf (white arrowheads). Abnormal tip cell 976 
morphology (blue arrowhead) remain in SKF96365-treated embryos by 50hpf. Scale bars 50 977 
µm. f) SKF96365 treated embryos display increased frequency of abnormal vascular 978 
branching (stunted SeAs or incomplete DLAV anastomosis) by 50 hpf (unpaired t-test; 979 
p=<0.0001; t=14.28 DF=18. n=2 repeats, n=5 embryos per group). g) tmem33 expression is 980 
not significantly altered by SKF96365 treatment (unpaired t-test; t=0.911, DF=4, n=3 981 
repeats). h-j) SKF96365 reduces frequency of endothelial Ca2+ oscillations in 982 
Tg(fli1a:gal4FFubs3;uas-gcamp7a) embryos. Intensity projection over time showing calcium 983 
oscillations in control embryos, highlighting intensity change over duration of time-lapse 984 
(unpaired t-test; p=<0.05; t=2.594, DF=10, n=2 repeats, 3 embryos per group). k, l) Notch 985 
reporter expression is reduced in SeAs (white arrowheads) and DA (red arrowhead) of 986 
Tg(csl:venus) embryos. Scale bars 50 µm. m) DA expression of Notch reporter is reduced by 987 
SKF treatment (unpaired t-test, **p=0.0097, t=3.982 DF=15, 2 repeats, n=4 embryos per 988 
group). n, o) SKF96365 treatment reduces endothelial filopodia number (black arrowheads) 989 
and abnormal spade shaped tip cell morphology (blue arrowhead), in Tg(fli1a:lifeact-990 
mClover) embryos. Scale bars 5 µm. p) SKF96365 treatment reduces mean filopodia number 991 
per SeA per embryo by 26hpf (unpaired t-test; p=<0.05; t=2.525, DF=10, n=2 repeats, n=5 992 
embryos per group). Source data are provided as a Source Data file. 993 
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Figure 8: Proposed model for tmem33 function in endothelial cells during angiogenesis. 995 
When VEGFA binds to its cognate receptor e.g. Kdrl, the resulting phosphorylation of PLCγ 996 
generates inositol 1,4,5-trisphosphate (IP3) and this, in turn, binds to IP3 receptors on the ER 997 
membrane which release Ca2+ into the cytosol from intracellular stores. Our data suggest the 998 
VEGF-mediated release of Ca2+ from ER stores during angiogenesis is dependent on 999 
Tmem33 function within the ER membrane. Furthermore, resultant Ca2+ oscillations 1000 
generated in tip cells downstream of Vegfa contribute to phosphorylation of ERK and 1001 
induction or maintenance of downstream targets including Dll4/Notch signalling, to co-1002 
ordinate cellular behaviours during vascular morphogenesis. PM; plasma membrane, ER; 1003 
endoplasmic reticulum 1004 
 1005 
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